Non-Coding RNA Assays Market size is projected to cross USD 630 million by the end of 2035, growing at a CAGR of 14% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of non-coding RNA assays was over USD 235 million. The growth of the market can be attributed to the increasing investment in medical research. Further, the need for assays that can accurately detect and quantify ncRNAs is being driven by the increase in research activities that use these molecules, which is also expected to add to the market growth. As of 2018, total U.S. spending on medical and health research and development (R&D) increased by over 6%.
In addition to these, factors that are believed to fuel the market growth of non-coding RNA assays include the surging government initiatives to promote life science research projects. For instance, in life sciences, research initiatives, non-coding RNA (ncRNA) tests have grown in importance, as they provide information on the roles and control mechanisms of ncRNAs in the cell. Additionally, the growing advancements in technology have enabled the development of more sensitive and accurate ncRNA detection assays, which are predicted to present the potential for market expansion over the projected period.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~14% |
|
Base Year Market Size (2022) |
~ USD 235 Million |
|
Forecast Year Market Size (2035) |
~ USD 630 Million |
|
Regional Scope |
|
End-user (Laboratories, Research Centers, Hospitals, Ambulatory Surgical Centers)
The global non-coding RNA assays market is segmented and analyzed for demand and supply by end-user into laboratories, research centers, hospitals, ambulatory surgical centers, and others. Out of the five end-users, the research centers segment is estimated to gain the largest market share in the year 2035. The growth of the segment can be attributed to the increasing prevalence of chronic diseases across the globe. For instance, since ncRNA tests have the potential to serve as biomarkers for illness diagnosis and prognosis, their application in research institutions is becoming more and more crucial. In addition, for a number of illnesses, including cancer, cardiovascular disease, and neurological disorders, ncRNA expression patterns can be employed as biomarkers. Today, an approximate 133 million Americans, or nearly fifty percent of the population, have at least one chronic disease, including hypertension, cardiovascular disease, or arthritis. This figure is 15 substantially larger than a decade ago, and it is projected to surpass 170 million by 2030.
The global non-coding RNA assays market is also segmented and analyzed for demand and supply by end-user into laboratories, research centers, hospitals, ambulatory surgical centers, and others. Amongst these five segments, the laboratories segment is expected to garner a significant share in the year 2035. Using ncRNA assays in laboratory settings is a fast-developing discipline as it offers a potent tool for comprehending how gene expression is regulated and assists in locating possible treatment targets. Besides this, the expression of diverse ncRNA types, including microRNAs, long non-coding RNAs, and small interfering RNAs, in various tissues and cell types may be examined using ncRNA assays in laboratories. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Size |
|
|
By End User |
|
North American Market Forecast
The market share of non-coding RNA assays in North America, amongst the market in all the other regions, is projected to grow with the highest CAGR by the end of 2035. The growth of the market can be attributed majorly to the availability of a large number of biotechnology and pharmaceutical companies. The development and marketing of non-coding RNA tests are made possible by a large number of biotechnology and pharmaceutical firms in the region. For instance, the numerous biotechnology and pharmaceutical firms can contribute to the advancement and commercialization of non-coding RNA tests, resulting in enhanced illness detection and the creation of novel treatment approaches. Further, the increasing government funding for research and development activities is also anticipated to contribute to the market growth in the region. In addition, the region's expanding healthcare industry is also anticipated to boost market growth during the forecast period. As per data, more than 60% of newly approved drugs in the US are the result of work done by small biotech companies.
Europe Market Forecast
The European non-coding RNA assays market is estimated to be the second largest and is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the presence of a large number of academic research institutions. For instance, non-coding RNA assays in the region may be significantly impacted by the presence of academic research institutes. These organizations frequently have access to resources such as skilled researchers, and well-equipped labs that can assist in non-coding RNA research, which as a result is anticipated to contribute to the market growth in the region.
APAC Market Statistics
Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the growing investment in biotech companies. For instance, as the biotechnology industry in the region is growing, it is likely that more companies are assumed to invest in research and development of non-coding RNA assays, which is expected to lead to the development of new technologies and tools for detecting and measuring non-coding RNAs. In addition, this is projected to speed up the search for novel illness biomarkers and the creation of non-coding RNA-targeting medications. Further, the surging development and adoption of advanced biotechnology in developing countries, including, India, China, and Japan, is also anticipated to contribute to the market growth in the region.
QIAGEN introduced QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit, to speed up the identification of DNA variants and RNA sequencing in low input samples. Further, the new solutions are based on enhanced chemistry that reduces the time required for library construction of DNA samples and establishes new criteria for processing materials in order to identify their nucleic acid sequences.
C D Genomics launched Whole Exome Sequencing, to extend its sequencing portfolio. Further, DNA sections known as exomes play a direct role in protein coding, and this approach is mostly employed to discover and investigate mutations in coding and UTR regions.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?